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A 43-year-old man presented to our genito-urinary clinic 
with a 3-month history of weight loss, poor appetite 
and recurrent genital ulcers. He had a past history of 
ischaemic heart disease and non-insulin-dependent 
diabetes mellitus. His medications included clopidrogel, 
gliclazide, metformin, atenolol, ramipril and simvastatin. 
On examination he was cachexic and had oral candidosis 
and penile ulcers typical of genital herpes (subsequently 
confirmed by a polymerase chain reaction test). Other 
findings were unremarkable. He tested positive for HIV 
antibodies. 
The patient was prescribed fluconazole for the oral 
candidosis and co-trimoxazole for prophylaxis against 
pneumocystis pneumonia. A follow-up appointment 
was made for 2 weeks’ time. However, 7 days later he 
was admitted complaining of muscle aches and difficulty 
in walking. His temperature was 39oC. He was unable 
to get up from a sitting position. There was no muscle 
tenderness, but he had significant weakness of hip flexors 
and extensors. Power distally was normal. Knee reflexes 
were normal and ankle reflexes were depressed. He had 
no bladder or bowel symptoms. The upper limbs and 
cranial nerves were normal. A urine specimen was dark 
and dipstick urinalysis showed 3+ red blood cells (RBCs) 
with no casts or proteins. The blood pressure was 140/70 
mmHg. Urine microscopy and culture showed nil RBCs 
and no growth. Laboratory evaluation revealed sodium 
125 mmol/l, potassium 6.0 mmol/l, urea 35.6 mmol/l, 
creatine 280 µmol/l, phosphate 0.77 mmol/l, calcium 2.42 
mmol/l, magnesium 1.05 mmol/l, alanine transaminase 
418 U/l, gammaglutaryl transferase l 743 U/l, alkaline 
phosphatase 460 U/l, albumin 25 g/dl, haemoglobin 
10.9 g/dl, white blood cells 12.10×109, platelets 312×109, 
creatine kinase 18 123 U/l, lactate dehydrogenase 1 608 
U/l (normal 220 - 450 U/l), HIV viral load 334 120 copies/
ml, and CD4 count 28 cells/µl (3.3%). Hepatitis B surface 
antigen was positive. Ultrasound scans of the ureters 
and bladder were normal. 
The patient was started on intravenous fluid 
therapy. Simvastatin, fluconazole and ramipril were 
discontinued. Within 3 weeks his muscle strength had 
improved with normalisation of the creatine kinase 
level and renal function. He continued to be pyrexial 
with no obvious focus of infection and rapidly went 
into respiratory failure requiring ventilatory support. 
A chest X-ray showed extensive alveolar opacification 
with confluent consolidation. He was treated for 
presumed pneumocystis pneumonia with high-dose 
co-trimoxazole. Mycobacterium tuberculosis was 
eventually cultured from a bronchial aspirate, a bone 
marrow aspirate and an early-morning urine specimen. 
He commenced quadruple therapy for tuberculosis 
followed by antiretrovirals (Truvada and efavirenz) 2 
weeks later. He made a full recovery.
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We report a case of rhabdomyolysis and acute renal failure in a 43-year-old man newly diagnosed with HIV 
and hepatitis B co-infection. Rhabdomyolysis was possibly induced by co-administration of simvastatin and 
fluconazole. Underlying hepatitis may have increased the risk of rhabdomyolysis by decreasing the metabolism of 
simvastatin. Few case reports link the development of rhabdomyolysis with the co-administration of these two 
drugs. This case calls for extra pharmacovigilance with proper patient education when prescribing drugs with 
potential for adverse interactions.
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A 25-year-old man was diagnosed with tuberculosis 
(TB) on sputum testing. He had symptoms typical of 
TB – weight loss, night sweats and chronic cough. His 
baseline CD4+ count was 134/µl (12%). He was mildly 
anaemic, with a haemoglobin concentration of 11.3 g/
l (normochromic and normocytic). Apart from mildly 
raised gamma-glytamyl transpeptidase (GGT) there were 
no other problems.  
The patient was started on antiretrovirals (ARVs) 
(stavudine (d4T), lamivudine (3TC) and efavirenz (EFV)) 
only 11 days after the start of TB treatment. The ARVs 
were started at the same time as co-trimoxazole 
(Bactrim). 
On day 24 of TB treatment, he presented for admission 
with the following:
n fever 
n  rash (macular papular) without involvement of 
mucous membranes 
n  cough as before 
n  increased GGT and alkaline phosphatase (now at 
three times the upper limit of normal) but normal 
transaminases. 
DIFFERENTIAL DIAGNOSIS
n  TB immune reconstitution inflammatory syndrome 
(IRIS) – while the timing suggests this, the presence 
of a rash is unusual.
n  Drug reaction – the patient had fever. If we believe this 
to be a drug reaction, we need to stop the offending 
drug.
n  EFV – reactions to this drug tend to occur on the 11th 
to the 14th day: after start of treatment, so in terms 
of timing it is still a possible cause. It is common and 
occurs in about 17% of patients. Less than1% of 
patients have a sufficiently severe reaction to warrant 
stopping the drug (Stocrin package insert).
Rhabdomyolysis is a musculoskeletal condition 
characterised by muscle weakness, an elevated creatine 
kinase level and myoglobinuria. The causes can be 
broadly classified into four categories, namely trauma 
related, excessive muscle activity, hereditary enzyme 
defects and medical causes. Medical causes include 
hypoxia, metabolic disorders, infections, temperature 
alterations and drugs.1 Simvastatin is metabolised via 
the cytochrome P450 (CYP3A4) system. Concomitant 
administration of simvastatin and drugs that inhibit the 
CYP3A4 system can increase serum concentrations of 
simvastatin.  Our patient developed rhabdomyolysis soon 
after commencing fluconazole. The underlying hepatitis 
coupled with the inhibitory effect of fluconazole on 
cytochrome CY3A4 may have led to increased serum 
levels of simvastatin leading to rhabdomyolysis. There 
are few case reports of rhabdomylysis developing after 
co-administration of simvastatin and fluconazole,2 but 
rhabdomyolysis following primary HIV infection (PHI), 
infection with M. tuberculosis and treatment with high-
dose co-trimoxazole has been reported.3-5 Increasing 
life expectancy of HIV-positive patients will mean 
increasing co-morbidities requiring pharmacological 
treatment. Awareness of the potential adverse drug 
interaction between statins and the azoles, macrolides 
and antiretrovirals, especially in patients with underlying 
liver or renal disease, is important.
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n  Co-trimoxazole – a rash is reported in about 3.5% of 
patients and is most common in those who are HIV 
positive. Of all the drugs this is the least important, 
as there are alternative drugs that can be used for 
prophylaxis. While dapsone is inferior to Bactrim as 
prophylaxis for Pneumocystis jiroveci pneumonia 
(PCP), it is still a viable option.
n  TB treatment – rifampicin, isoniazid and pyrazinamide 
may cause a hypersentivity reaction with flu-like 
symptoms and uticaria. A rash from anti-TB treatment 
usually results from pyrazinamide, not rifampicin. If 
minor rashes and acneiform reactions to rifampicin 
occur, they are almost always self-limiting or can be 
treated symptomatically.
MANAGEMENT
Co-trimxazole was stopped, ARVs were stopped, TB 
treatment was stopped, and the patient was given 
antihistamines and steroids (prednisone 20 mg twice a 
day). The rash and fever settled.
The idea of drug challenge is to identify the drug 
responsible for the reaction. Drug challenge starts 
with a small dose of with the TB drug least likely to 
be responsible for the reaction (a small dose is used 
because if a reaction occurs it will be less severe than the 
reaction to a full dose). The dose is gradually increased 
over 3 days.1 
n   INH: is this the drug least likely to be responsible, so 
this is where to start.
n  The procedure is repeated, adding in one drug at a time. 
A reaction after adding a particular drug identifies that 
drug as the one responsible for the reaction. There is 
no evidence that this challenge process gives rise to 
drug resistance.
n   If the drug responsible for the reaction is pyrazinamide, 
ethambutol or streptomycin, TB treatment is resumed 
without the offending drug. If possible, the offending 
drug is replaced with another drug. It may be necessary 
to extend the treatment regimen. This prolongs the 
total time of TB treatment, but decreases the risk of 
relapse.
The patient tolerated this process well and did not 
develop a rash again. We concluded that EFV was the 
most likely offender. He completed his TB treatment and 
was then started on a protease inhibitor (PI)-containing 
regimen. He is now well. 
1.  Treatment of TB, Guidelines for National Programs, WHO. http://whqlibdoc.who.
int/hq/2003/WHO_CDS_TB_2003.313_eng.pdf (accessed 11 September 2008).
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Patients diagnosed with tuberculosis (TB) and then 
commenced on antiretroviral therapy (ART) are often 
on several drugs that can cause a hypersensitivity 
drug reaction. Such reactions may take the form of 
a drug rash (which may evolve to a Stevens-Johnson 
syndrome or toxic epidermal necrolysis), hepatitis, a 
drug fever or a combination of these. These reactions 
result in considerable morbidity directly and indirectly 
because they cause interruptions in optimal treatment 
for the TB and HIV.
Although recurrence of fever is a manifestation of TB 
IRIS, a maculopapular skin rash is not. In this case, the 
maculopapular rash represents a hypersensitivity drug 
reaction with associated fever. The patient described did 
not appear to have an associated drug-induced hepatitis, 
as this typically manifests with raised transaminases. 
His cholestatic liver function derangement was probably 
related to TB in the liver.
In this case the drugs that could have been responsible 
for the hypersensitivity reaction are co-trimoxazole, 
efavirenz (these are the two most likely culprits) and 
any of the TB medications (rifampicin, isoniazid, 
pyrazinamide, ethambutol and streptomycin can all 
result in hypersensitivity drug rashes). At our hospital we 
would follow similar principles of management to that 
followed by the author, but there are certain differences 
in our approach. While neither approach is necessarily 
more correct, a ‘second opinion’ on management of this 
case may be of interest to the reader.
The presence of fever in association with a drug rash 
means that the hypersensitivity reaction is severe and 
systemic. Administration of the drugs most likely to be 
the culprits must therefore be interrupted. In this case 
rather than interrupting all therapy we would interrupt 
only those medications that were the most probable 
culprits, as follows:
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1.   In terms of ART, we would stop efavirenz and 
continue the two nucleoside reverse transcriptase 
inhibitors (NRTIs), 3TC and D4T. It is possible to interrupt 
efavirenz (or nevirapine) for 5 - 7 days and continue 
the two NRTIs because of the long half-life of the non-
nucleoside reverse transcriptase inhibitors (NNRTIs), 
which means that the patient is still effectively on three 
drugs for this period. Once the reaction has resolved 
(this usually occurs within this 5 - 7-day window) we 
would add Kaletra to the two NRTIs. (Kaletra would 
need to be increased to double dose once rifampicin 
was successfully reintroduced because of rifampicin’s 
induction of lopinavir metabolism.)
2.   We would interrupt all the TB treatment the patient 
was taking. If the patient was in the early stages of TB 
treatment, as in this case, we would put the patient on 
two or three alternative TB drugs that he was not on at 
the time of the reaction (e.g. streptomycin, ofloxacin, 
ethionamide) so as to continue TB treatment before 
rechallenge. Once the reaction had resolved, we would 
then use these drugs as a backbone upon which to 
rechallenge one first-line TB drug at a time at 3-day 
intervals starting with a low dose and increasing to full 
dose. We would use the following order: ethambutol, 
isoniazid, rifampicin, then pyrazinamide. The alternative 
TB drugs used as a backbone can be stopped if the first-
line drugs are all successfully reintroduced.
When rechallenging after a skin reaction it is important 
to monitor the patient’s temperature, observe his or 
her skin and ask about skin symptoms. Even mild skin 
symptoms such as burning or itching after a dose should 
alert the clinician that that drug should be avoided. The 
patient may be able to restart all TB medications in this 
situation, as co-trimoxazole and efavirenz are the most 
likely culprits. However, if a reaction occurs to one of 
the TB drugs on rechallenge, that drug will need to be 
avoided and TB treatment may need to be extended (e.g. 
to 9 months if pyrazinamide is omitted). 
3.   We would stop co-trimoxazole and not rechallenge it, 
given that it was being used as primary prophylaxis and 
the patient is now on ART which will restore protection 
against PCP with time.
Our approach in such a situation is therefore to 
interrupt the likely culprit drugs while continuing safer 
treatments for TB and HIV as the reaction settles and 
then rechallenge in a similar way to that described 
by the author. However, when a drug reaction is life 
threatening (e.g. severe hepatocellular injury with 
very high transaminases, hepatic encephalopathy or 
raised international normalised ratio (INR), or Stevens-
Johnson syndrome) we would manage differently: ALL 
therapies the patient was taking at the time would be 
stopped in the acute situation.
For drug reactions we do not prescribe systemic 
corticosteroids. The evidence base for their use is 
controversial and contradictory. Some studies have 
demonstrated an increased risk of sepsis in patients 
with Stevens-Johnson syndrome, and as one cannot 
be sure that a skin rash will not evolve to this when a 
patient is first seen, we avoid them.
New Publication: HTB South 
Distributed with this issue of the 
Journal is the first issue of HTB South 
- a new quarterly review of the latest 
research and other HIV treatment 
news. HTB South has particular 
implications for clinical practice.
HTB South is produced by HIV 
i-Base, an HIV-positive led treatment 
information service based in 
London, UK.




HTB South is supported by the 
UK Department for International 
Development (DfID)
HTB.indd   1 10/10/08   8:52:16 AM
severe.indd   56 10/14/08   9:58:13 AM
